Skip to content
2000
Volume 21, Issue 3
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Background: Epidermal growth factor receptor (EGFR) is a validated and therapeutically amenable target, and inhibition of the EGFR signaling pathway has emerged as an attractive target for cancer therapy.Methods: The present work was designed to synthesize and evaluate the antiproliferative activity of a novel series of 3,9-dioxatetraasteranes as potential inhibitors of EGFR. All target compounds were evaluated for antiproliferative activity against A549 and HepG2 cell lines.Results: Among the target compounds, compound B13 displayed the most potent antiproliferative activity against A549 with IC = 4.31 μM and HepG2 with IC = 6.92 μM. In addition, a molecular docking study was performed to investigate the binding mode and binding capacity with EGFR (PDB code: 1M17). Conclusion: The results indicated that 3,9-dioxatetraasteranes may be promising potential EGFR inhibitors.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180819666220928151144
2024-03-01
2025-01-06
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180819666220928151144
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test